Table 1

Characteristics of study subjects in the CAncer Prostate in Sweden 1 study

Age at diagnosis
45–65 years66–80 years
n%n%
T stage
 T030.4530.46
 T125939.2420030.96
 T223435.4520832.20
 T314421.8220732.04
 T4203.03284.33
 Missing4433
N stage
 N015785.796677.65
 N12614.211922.35
 Missing521594
M stage
 M032883.0425079.62
 M16716.966420.38
 Missing309365
Gleason score
 ≤4294.67244.21
 57912.726311.05
 623638.0018532.46
 717728.5018832.98
 8538.537012.28
 9406.44376.49
 1071.1330.53
 Missing83109
Differential
 GI3513.513413.23
 GII15459.4615158.75
 GIII7027.037228.01
 Missing445422
PSAa levels (ng/ml)
 <4497.46264.07
 4–9.9926440.1816926.45
 10–19.9913921.1615223.79
 20–49.999214.0012820.03
 50–99.99497.467712.05
 ≥100649.748713.62
 Missing4740
  • a PSA, prostate-specific antigen.